Novo Nordisk's Quiet Erosion: Quality Questions and Copycat Threats Test the GLP-1 Kingpin

Novo Nordisk shares down 28% from peak amid manufacturing issues, generic competition, and a Deutsche Bank downgrade to Sell.

There's a particular kind of pressure that builds on a market leader when nothing dramatic happens. No single catastrophe, no headline-grabbing trial failure — just a slow accumulation of small fractures that, taken together, tell a more troubling story. Novo Nordisk is living that reality right now.

The Danish pharmaceutical giant's shares are trading at roughly 39.45 euros, still 28 percent below their 52-week peak of 54.86 euros. The decline hasn't been a crash; it's been a grinding, persistent slide that reflects a growing list of concerns — from manufacturing quality to the increasingly visible shadow of generic competition.

A Manufacturing Stumble With Echoes Beyond the Product

Late last week, Reuters reported that US biotech firm Scholar Rock had withdrawn its European regulatory application for a spinal muscular atrophy treatment. The reason? Problems at a production facility owned by Novo Nordisk. Scholar Rock says it will pivot to an alternative manufacturing site and resubmit the application at a later date.

For Novo Nordisk, the drug in question isn't its own — but that almost misses the point. The episode shines an uncomfortable light on quality control across the company's production network, precisely when global demand for its weight-loss treatments is straining every available line.

When you manufacture for third parties, those facilities must meet the same standards as the lines producing Ozempic and Wegovy. A stumble of this kind raises questions about whether the blistering growth of recent years can continue without friction — and whether the company's operational rigor is keeping pace with its commercial ambitions.

The Copycats Are Circling

Meanwhile, competition is emerging from corners that seemed implausible just a few years ago. Poland's Celon Pharma told Reuters that its experimental semaglutide product, Reduzek, posted similar results to Ozempic and Wegovy in an early bioequivalence study. To be clear: this is an early-stage trial, not an approval, not a market-ready product.

But the signal matters. Semaglutide — once Novo Nordisk's proprietary crown jewel — is becoming technically replicable. As patents expire and generics clear regulatory hurdles, the pricing pressure that has so far come mainly from direct rival Eli Lilly could intensify from a new direction entirely.

This is the broader industry narrative converging: GLP-1 therapies have become one of the most lucrative pharmaceutical markets in history, and where billions accumulate, competitors follow — whether established players or ambitious generics manufacturers from Eastern Europe and Asia.

Wall Street's Skepticism Hardens

The Deutsche Bank's decision to downgrade Novo Nordisk from "Hold" to "Sell" on Thursday crystallized the market's unease. The bank cut its price target to 265 Danish kroner from 290 kroner, citing weakening growth prospects for 2027, pipeline setbacks, and the longer-term threat of patent expirations on core products.

The most significant pipeline concern centers on ziltivekimab, an anti-inflammatory candidate that had been viewed as a potential future growth driver. The combination of a dimming growth outlook and doubts about the next generation of blockbuster successors proved too much for the bank's analysts.

The stock's reaction was telling. Shares closed Tuesday at 38.99 euros, down 11 percent year-to-date, and trading about 3.0 percent below the 200-day moving average — a technical signal that the medium-term downtrend remains intact.

What makes the downgrade particularly noteworthy is its timing: it landed on the same day Chinese regulators accepted the filing for the oral Wegovy version. Even positive news from the crucial Chinese market couldn't offset concerns about the company's medium-term earnings power — a sign that investors are now focused on structural risks rather than individual regulatory wins.

A Pipeline Still in Motion

None of this means Novo Nordisk has stopped innovating. The company continues to advance its research agenda on multiple fronts. China has accepted the oral Wegovy application. In Greece and Cyprus, Myriam Mezher takes over as managing director on September 1. The partnership with Novonesis exploring whether microbiome products can enhance GLP-1 medications continues, though results aren't expected until the second half of 2027.

External collaborations are also progressing. Partner Lexicon Pharmaceuticals received its third milestone payment of $10 million in 2026 after hitting a patient-dosing milestone in the obesity development program for LX9851.

These are the building blocks of a long-term strategy — but they're not short-term catalysts. The market's technical indicators reflect this ambivalence: the RSI sits at 44.5, signaling neither overbought nor oversold conditions. Investors are feeling their way forward without committing to a clear direction.

The real question hanging over Novo Nordisk isn't whether it can continue growing. It's whether the company can sustain its pace without fraying at the edges — in manufacturing, in its patent fortress, in the pipeline that must eventually replace Ozempic and Wegovy. The upcoming capital markets day will offer management a chance to address those doubts directly. Whether the answers convince a skeptical market remains very much an open question.